Libtayo is Regeneron PD-1 blocking antibody for advanced skin and lung cancers.
Competing Products
Regeneron Pharmaceuticals
Discovering, developing, and commercializing pharmaceutical products for serious medical conditions in the US.
Founded
1988Discovering, developing, and commercializing pharmaceutical products for serious medical conditions in the US.
Regeneron Pharmaceuticals, Inc., founded in 1988 and headquartered in Tarrytown, New York, is dedicated to discovering, developing, manufacturing, and commercializing medicines for serious medical conditions. The company's core mission is to use the power of science to bring new medicines to patients in need. Regeneron's product portfolio includes EYLEA, an injection for various eye diseases, Dupixent for atopic dermatitis and asthma, and Libtayo for certain cancers. The company focuses on the U.S. market but has a global impact through its innovative treatments.
Notable affiliated individuals include co-founders Leonard Schleifer and George Yancopoulos, who have been instrumental in the company's scientific advancements. Regeneron has attracted significant investment from entities like Sanofi. Key achievements include the development of groundbreaking therapies like EYLEA and Dupixent, which have transformed treatment paradigms in their respective fields. Regeneron's impact is profound, with its medicines improving the lives of millions of patients worldwide.
Companies similar to Regeneron Pharmaceuticals include Bristol Myers Squibb, Eikon Therapeutics, Memento Medicines and Genentech.
Regeneron Pharmaceuticals was founded in 1988.
Regeneron Pharmaceuticals' headquarters is located in Tarrytown, NY, US.
Regeneron Pharmaceuticals' most recent funding round was for $5M (USD) in October 2023.
As of Oct 18, 2023, Regeneron Pharmaceuticals has disclosed funding of $13.9M (USD). Undisclosed round amounts are excluded.
Regeneron Pharmaceuticals has 11,851 employees as of Feb 6, 2024.
Genentech
gene.com